BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Argus Health
Daiichi Sankyo
Chinese Patent Office
US Department of Justice
US Army

Generated: December 17, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Details for Patent: ► Subscribe

Title: Methods for treatment of sundamaged human skin with retinoids
Abstract:Various effects of photoaging or sundamage of skin including impairment of differentiation of epidermal epithelial cells and loss of collagen fibers, abnormal changes in elastic fibers and deterioration of small blood vessels in the dermis of the skin are retarded by applying topically to the epidermis in a maintenance therapy program effective amounts of retinoids including retinoid derivatives and stereoisomers thereof such that epithelial growths are substantially reduced and prevented and the skin substantially regains and maintains its firmness, turgor and elasticity. Moreover, with persistent treatment dermal blood cells and vessels increase and the epidermis and dermis thicken, resulting in improved ability of the skin to sense, resist and recover from irritation or injury. Further, hyperpigmentation, lines and wrinkles due to aging are reduced and prevented. The treatment is particularly useful for human facial skin and preferably applied in amounts insufficient to cause excessive irritation.
Inventor(s): Kligman; Albert M. (N/A)
Filing Date:Mar 08, 1988
Application Number:07/228,212
Claims:1. A method for retarding and reversing the loss of collagen fibers, abnormal changes in elastic fibers, and deterioration of small blood vessels in sundamaged human skin, comprising applying topically to the surface of the skin a composition comprising effective amounts of a retinoid selected from the group consisting of 2-(4-Carboxybenzamido)-5,6,7,8-tetrahydro-5,5,8,8-tetramethylphaphthalene; 2-[N-(4-Carboxyphenyl)carbamoly]-5,6,7,8-tetrahydro-5,5,8,8-tetramethyll-n aphthalene; 1-[3,5-(Di-tert-butyl)benzoyl]-2-(4-Carboxyphenyl)ethene; TTNT 2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-6-benzo (b) thiophene carboxylic acid; TTNF 2-(t,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-6-benzo (b) furancarboxylic acid; TTNI 2-(5,6,7,8-tetraphydro-5,5,8,8-tetramethyl-2-naphthyl)-6-indolecarboxylic acid; TTNN 2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2naphthyl)-6-naphthalene carboxylic acid; p-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-anthracenyl) benzonic acid; and esters or amides of 13 trans retinoic acid or 13-cis retinoic acid wherein the --OH group of the carboxylic acid (--COOH) group is substituted by --OR.sup.1 or NR.sup.2 R.sup.3, wherein R.sup.1, R.sup.2 and R.sup.3 are such that these esters or amides can be converted to 13-trans retinoic acid or 13-cis retinoic acid through hydrolysis, metabolism, or cleavage, in a non-toxic, dermatologically acceptable vehicle in a program of maintenance therapy, whereby the skin substantially regains and maintains its firmness, turgor and elasticity during said therapy, said composition and amounts of retinoid therein being selected so as to provide a dose for application which is insufficient to cause excessive irritation.

2. A method according to claim 1 wherein said skin is human facial skin.

3. A method according to claim 1 wherein said vehicle is an emollient vehicle.

4. A method according to claim 1 wherein said dose is a sub-irritating dose.
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Federal Trade Commission
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch: